Allakos Inc

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --     -- Top-line safety and efficacy results from both studies expected in the second half of 2021 --

Allakos Initiates Patient Recruitment for AK002 Registrational Studies

Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Allakos (ALLK) Stock Might be a Great Pick

Allakos Inc (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Allakos Inc (ALLK) Rating Upgrade to Buy

REDWOOD CITY, Calif., May  11, 2020  (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the first quarter ended March 31, 2020.

Allakos Reports First Quarter 2020 Financial Results

-- Antolimab treatment provided durable symptom improvement and blood and tissue eosinophil depletion --    -- Symptomatic benefit increased with duration of antolimab treatment --

Allakos Announces Positive Interim Results from an Open-Label Extension Study of Antolimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis

-- Management to host conference call and webcast today at 5:00 pm ET --  REDWOOD CITY, Calif., March  24, 2020  (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today reported the initiation of three clinical studies of antolimab: a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD), a Phase 2/3 study in eosinophilic esophagitis (EoE), and a Phase 1 study of subcutaneously administered antolimab in healthy volunteers. The Phase 3 EG and/or EoD study and the Phase 2/3 EoE study follow positive results from ENIGMA, the Company’s multicenter, randomized, double-blind, placebo-controlled Phase 2 study in patients with EG and/or EoD.

Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies

-- Antolimab (AK002) reduced gastrointestinal symptoms by 64 percent in patients with mast cell gastrointestinal disease --    -- Management to host conference call and webcast today at 5:00 pm ET --

Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease

Allakos Does It Again; bluebird And Sunesis Data: The Good, Bad And Ugly Of Biopharma

Shares of Allakos Inc.  rallied 37% in afternoon trading, to a record high.

Allakos stock jumps in afternoon trading

REDWOOD CITY, Calif., Oct.  28, 2019  (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced upcoming presentations at the American College of Gastroenterology 2019 Annual Scientific Meeting. The Company and its collaborators will deliver one oral and four poster presentations at the event being held in San Antonio, Texas from October 28 to 30, 2019.

Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting

Guardant Health Inc

Twist Bioscience Corp

Find out why these new healthcare stocks keep climbing, while most of their peers have underwhelmed.

3 Healthcare IPOs From 2018 That Have Already Doubled

Investors were enthused about this biotech's positive phase 2 results for its lead investigational therapy, AK002.

Why Allakos Stock Skyrocketed 154% in August

Vertex Pharmaceuticals

Biohaven Pharmaceutical Hld

Amicus Therapeutics

Jazz Pharmaceuticals

Golden crosses and death crosses are common signals in technical analysis and refer to the relationship between short-term and long-term moving averages.

Vertex Pharmaceuticals and Other Biotech Stocks With Recent Golden Crosses

As of late, it has definitely been a great time to be an investor Allakos.

Will Allakos Continue to Surge Higher?

News for Allakos Inc Stock (ALLK)